CLINICAL IMMUNOLOGY
Serum anti-collagen type IV IgM antibodies and development of diabetic nephropathy in diabetics with essential hypertension
Submission date: 2015-07-16
Final revision date: 2015-09-30
Acceptance date: 2015-11-06
Publication date: 2016-01-20
Cent Eur J Immunol 2016;41(1):86-92
KEYWORDS
ABSTRACT
Background and aims: Arterial hypertension and diabetic vascular complications are connected with an elevated degradation of elastic tissue. This process leads to an increased production of antibodies to collagen type IV (ACIV Abs). In the present investigation we studied whether the serum levels of antibodies (IgG, IgM and IgA) to collagen are related with microvascular complications.
Material and methods: Serum levels of antibodies to collagen type IV (ACIV) IgG, IgM and IgA were measured using an ELISA method in 93 patients with type 2 diabetes mellitus and arterial hypertension (AH) (mean age 61.4 ±11.3 years, diabetes duration 9.88 ±3.12 years; hypertension duration 9.28 ±4.98). These values were compared to serum antibodies to CIV in 42 age and sex matched controls.
Results: ACIV IgM antibodies levels in patients with AH and T2DM were statisticaly significantly higher than controls 0.178 (0.145÷0.220) vs. 0.142 (0.118÷0.173) (KW = 6.31; p = 0.01). Group 1 (patients with microvascular complications) showed significantly higher levels of ACIV IgM than controls 0.180 (0.136÷0.223) vs. 0.142 (0.118÷0.173) (KW = 5.03; p = 0.02). Patients from Group 2 showed statistically significantly higher levels of ACIV IgM than controls 0.176 (0.151÷0.202) vs. 0.142 (0.118÷0.173) (KW = 6.15; p = 0.01). ACIV IgM antibodies showed correlation with microalbuminuria (r = 0.21); (p = 0.04), BMI (r = 0.19); (p = 0.04), creatinine clearance (r = –0.36); (p = 0.01) and GFR (r = –0.34); (p = 0.02).
Conclusions: Our study showed an association between elevation of serum levels of ACIV IgM and development of diabetic nephropathy. We suggest that levels of ACIV IgM can be useful method for identfying a high risk for development of diabetic nephropathy.
Material and methods: Serum levels of antibodies to collagen type IV (ACIV) IgG, IgM and IgA were measured using an ELISA method in 93 patients with type 2 diabetes mellitus and arterial hypertension (AH) (mean age 61.4 ±11.3 years, diabetes duration 9.88 ±3.12 years; hypertension duration 9.28 ±4.98). These values were compared to serum antibodies to CIV in 42 age and sex matched controls.
Results: ACIV IgM antibodies levels in patients with AH and T2DM were statisticaly significantly higher than controls 0.178 (0.145÷0.220) vs. 0.142 (0.118÷0.173) (KW = 6.31; p = 0.01). Group 1 (patients with microvascular complications) showed significantly higher levels of ACIV IgM than controls 0.180 (0.136÷0.223) vs. 0.142 (0.118÷0.173) (KW = 5.03; p = 0.02). Patients from Group 2 showed statistically significantly higher levels of ACIV IgM than controls 0.176 (0.151÷0.202) vs. 0.142 (0.118÷0.173) (KW = 6.15; p = 0.01). ACIV IgM antibodies showed correlation with microalbuminuria (r = 0.21); (p = 0.04), BMI (r = 0.19); (p = 0.04), creatinine clearance (r = –0.36); (p = 0.01) and GFR (r = –0.34); (p = 0.02).
Conclusions: Our study showed an association between elevation of serum levels of ACIV IgM and development of diabetic nephropathy. We suggest that levels of ACIV IgM can be useful method for identfying a high risk for development of diabetic nephropathy.
REFERENCES (26)
1.
Laviades C, Varo N, Fernandez J, et al. (1998): Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98: 535-540.
2.
Klatt AR, Becker AK, Neacsu CD, Paulsson M (2011): The matrilins: modulators of extracellular matrix assembly. Int J Biochem Cell Biol 43: 320-330.
3.
Coelho NM, González-García C (2011) Arrangement of type IV collagen on NH2 and COOH functionalized surfaces Biotechnol Bioeng 108: 3009-3018.
4.
Erben U, Neumann U, Schuppan D (2011): Hydroxyproline-containing collagen analogs trigger the release and activation of collagen-sequestered proMMP-2 by competition with prodomain-derived. Fibrogenesis Tissue Repair 4: 211-215.
5.
Nikolov AG, Nicoloff G, Tsinlikov I, Tsinlikova I (2012): Anti-collagen type IV antibodies and the development of microvascular complications in diabetic patients with arterial hypertension. J IMAB 18: 144-148.
6.
Nicoloff G, Deliiyski T, Nikolov A (2010): Detection of serum collagen type IV and elastin derived peptides in patients with breast cancer. Diabetologia Croatica 41: 103-111.
7.
Kanie K, Narita Y, Zhao Y, Kuwabara F (2012): Collagen type IV specific tripeptides for selective adhesion of endothelial and smooth muscle cells. Biotechnol Bioeng 109: 1808-1816.
8.
Morillas P (2013): Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage. J Hypertens 31: 1611-1617.
9.
Kannel WB, Mcgee DL (1979): Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care; 2: 120-126.
11.
Rosenbloom J, Abrams WR, Mecham R (1993): Extracellular matrix for the elastic fiber. Faseb J 7: 165-168.
12.
American Diabetes Association. Diabetes (2001) Vital Statistics. Alexandria, VA, ADA.
13.
Susumu T, Uchugu T, Shoichi T (2003): Measurement of serum anti-type IV collagen antibody in diabetic patients. Annals of Gunma University School of Health Sciences 24: 87-91.
14.
Nicoloff G, Baydanoff S, Petrova C, Christova P (2002): Serum antibodies tocollagen type IV and development ofdiabetic vascular complications inchildren with type 1 (insulin-depen-dent) diabetes mellitus – a longitudinalstudy. Vascular Pharmacology 38: 143-147.
15.
Nicoloff G, Baydanoff S, Stanimirova N, et al. (2001): Serum collagentype IV in healthy children and childrenwith insulin-dependent diabetesmellitus. Clin Appl Immunol Invest 1: 165-168.
16.
Nicoloff G, Nikolov A, Dekov D (2005): Serum AGE-elastin derived peptides among diabetic children. Vascul Pharmacol 43: 193-197.
17.
Patel D, Menon R, Taite LJ (2010): Self-assembly of elastin-based peptides into the ECM: the importance of integrins and the elastin binding protein in elastic fiber assembly, Biomacromolecules, ACS Publications.
18.
González GE, Rhaleb NE, Nakagawa P, et al. (2013): N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats. Clin Sci (Lond) 126: 85-94.
19.
Yano Y, Hamanaka R, Nakamura M (2012): Smad, but not MAPK, pathway mediates the expression of type I collagen in radiation induced fibrosis. Biochem Biophys Res Commun 418: 457-463.
20.
Cohen P (2001): Serum type IV collagen in diabetic patients at risk for nephropathy. Diabetes Care 24: 1324-1327.
21.
Araki S, Haneda M, Koya D, et al. (2010): Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 33: 1805-1810.
22.
Peterszegi G, Mandet C, Texier S, et al. (1997): Lymphocytesin human atherosclerotic plaque exhibitthe elastin-laminin receptor:potentialrole in atherogenesis. Atherosclerosis 135: 103-107.
23.
Hu C, Sun L, Han Y, et al. (2015): Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy. Curr Med Chem 22: 24-28.
24.
Iida M, Yamamoto M, Ishiguro YS, et al. (2014): Urinary type IV collagen is related to left ventricular diastolic function and brain natriuretic peptide in hypertensive patients with prediabetes. J Diabetes Complications 28: 824-830.
25.
Enomoto D, Okura T, Nagao T, et al. (2012): Relationship between renal hemodynamics and urinary type IV collagen in patients with essential hypertension. Clin Exp Hypertens 34: 612-616.
26.
Fiseha T (2015): Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res 3: 16.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
